CFTR and cystic fibrosis: Lumacaftor with ivacaftor and elexacaftor-tezacaftor-Ivacaftor are CFTR modulators approved for use in the United States that help restore the function of the defective sodium chloride ion channel10 While their use has shown improved pulmonary outcomes in CF patients, their effect on the liver is not currently known.